Peking University publishes: New PET probe non-invasively displays the distribution of DR5 in patients with gastrointestinal tumors

Recently, the team of Director Yang Zhi of the Department of Nuclear Medicine of Peking University Cancer Hospital and the team of Director Wu Aiwen of the third ward of the Gastrointestinal Cancer Center have used advanced PET molecular imaging technology to target molecular probes with 89Zr-labeled death receptor 5 (DR5).

DR5 is overexpressed in colon cancer, gastric cancer, pancreatic cancer, lung cancer, cervical cancer and other tumors, but it is rarely expressed in normal tissues, showing significant differences

Studies have shown that, before the development of DR5 targeted therapy, the determination of tumor DR5 expression is very important

The corresponding authors of the study are Professor Yang Zhi, Chief Physician Li Nan of the Department of Nuclear Medicine, Chief Physician Wu Aiwen of Parenteral Three, and the first author is Dr.

Peking University Cancer Hospital, with its strong R&D capabilities for medical isotope drugs and excellent clinical translation results, in conjunction with the just released "Medical Isotope Medium and Long-term Development Plan (2021-2035)", it actively promotes the original research of domestic radiopharmaceuticals and faces new targets.

References: Shujing Wang†, Hua Zhu†, Yingjie Li†, Jin Ding, Feng Wang, Lixin Ding, Xinyu Wang, Jun Zhao, Yan Zhang, Yunfeng Yao, Tong Zhou, Nan Li*, Aiwen Wu*, Zhi Yang* .